• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Ampio Pharmaceuticals, Inc. (AMPE) Stock Price, News & Analysis

Ampio Pharmaceuticals, Inc. (AMPE) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.01

-$0

(0%)

Day's range
$0
Day's range
$0.01
50-day range
$0.001
Day's range
$0.0751
  • Country: US
  • ISIN: US03209T3077
52 wk range
$0
Day's range
$7.47


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -63.71
  • Piotroski Score 2.00
  • Grade Hold
  • Symbol (AMPE)
  • Company Ampio Pharmaceuticals, Inc.
  • Price $0.01
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $0.00
  • Day High $0.01
  • Year High $7.47

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/22/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$10.66
  • Trailing P/E Ratio -0.01
  • Forward P/E Ratio -0.01
  • P/E Growth -0.01
  • Net Income $-8,632,000

Income Statement

Quarterly

Annual

Latest News of AMPE

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Ampio Pharmaceuticals, Inc. Frequently Asked Questions

  • What is the Ampio Pharmaceuticals, Inc. stock price today?

    Today's price of Ampio Pharmaceuticals, Inc. is $0.01 — it has decreased by 0% in the past 24 hours. Watch Ampio Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Ampio Pharmaceuticals, Inc. release reports?

    Yes, you can track Ampio Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Ampio Pharmaceuticals, Inc. stock forecast?

    Watch the Ampio Pharmaceuticals, Inc. chart and read a more detailed Ampio Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Ampio Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on AMEX, exchange stock trades by Ampio Pharmaceuticals, Inc. stock ticker.

  • How to buy Ampio Pharmaceuticals, Inc. stocks?

    Like other stocks, AMPE shares are sold on stock exchanges such as AMEX. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Ampio Pharmaceuticals, Inc.'s EBITDA?

    Ampio Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Ampio Pharmaceuticals, Inc.’s financial statements.

  • What is the Ampio Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Ampio Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Ampio Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Ampio Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Ampio Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Ampio Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for Ampio Pharmaceuticals, Inc. for its last quarter?

    Ampio Pharmaceuticals, Inc. published it's last quarterly revenues at $245,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.